Comment from May 1, 2025

May 2025
Comment Received on Fentanyl, Fentanyl Analogues, and Other Opioids
90 FR 8840

In January 2025, the Commission requested comment on several issues relating to fentanyl, fentanyl analogues, and other opioids. As part of its statutory authority and responsibility to analyze sentencing issues, including operation of the federal sentencing guidelines, the Commission published the following issues for comment:

 Issues for Comment:

  1. The Commission seeks comment on whether it should consider revising §2D1.1 to add an enhancement for distribution of fentanyl, fentanyl analogues, and other opioids to individuals under the age of 21. If so, should the enhancement be defendant-based or offense-based? By how many levels should the enhancement increase base offense levels, and what is the basis for such increase? Should the Commission consider any other changes to §2D1.1 to address the harm in these cases?
  2. The Commission seeks comment on whether it should consider revising §2D1.1 to add an enhancement for fentanyl, fentanyl analogue, and opioid offenses involving the use of the dark web or other anonymizing technologies. If so, how should the Commission define or describe what technologies qualify for the enhancement? Should the enhancement be defendant-based or offense-based? By how many levels should the enhancement increase base offense levels, and what is the basis for such increase? Should the Commission consider any other changes to §2D1.1 to address the harm in these cases?
  3. The Commission seeks comment on whether it should consider revising §2D1.1 to add an enhancement for drug trafficking offenses involving fentanyl, a fentanyl analogue, or another synthetic opioid adulterated with xylazine or medetomidine. The Commission invites comment on xylazine and medetomidine, particularly their pharmacological effects, potential for addiction and abuse, the patterns of abuse and harms associated with their abuse, and the patterns of trafficking and harms associated with their trafficking. The Commission also invites comment on whether there are other adulterants to fentanyl, fentanyl analogues, and other synthetic opioids for which an enhancement should apply. If the Commission were to add an enhancement to §2D1.1 for drug trafficking offenses involving fentanyl, a fentanyl analogue, or another synthetic opioid adulterated with xylazine, medetomidine, or another adulterant should the enhancement be defendant-based or offense-based? By how many levels should the enhancement increase base offense levels, and what is the basis for such increase? Should the Commission consider any other changes to §2D1.1 to address the harm in these cases?


Submitters:

  • U.S. District Judge David Counts [10]
  • U.S. District Judge Susan D. Wigenton [14]
  • U.S. Department of Justice, Criminal Division [15]
  • Federal Public and Community Defenders [30]
  • Practitioners Advisory Group [48]
  • Probation Officers Advisory Group [52]
  • Tribal Issues Advisory Group [56]
  • Victims Advisory Group [59]
  • Drug Policy Alliance, American Civil Liberties Union, Campaign to Fight Toxic Prisons, et al.  [64]
  • Drug Policy Alliance [69]
  • FAMM [76]
  • Sydney Biggs [82]
  • Autumn Burris [83]
  • Whitney Carter  [87]
  • Antjuan Doss [88]
  • Anahita Khadang [89]
  • Lindsey London [90]
  • Josh Smith [92]
  • Je Villoria [93]
  • Desirae Webster [94]
  • Susie Whitiman [95]
  • Lewis Whitmire [96]